Efficacy by prior lines of therapy and cytogenetic risk status at baseline
| . | High risk . | Standard risk . | ||||||
|---|---|---|---|---|---|---|---|---|
| 1 Prior line . | ≥2 Prior lines . | 1 Prior line . | ≥2 Prior lines . | |||||
| KRd (n = 23) . | Rd (n = 18) . | KRd (n = 25) . | Rd (n = 34) . | KRd (n = 70) . | Rd (n = 72) . | KRd (n = 77) . | Rd (n = 98) . | |
| PFS, median mo | 24.1 | 14.0 | 22.2 | 12.0 | 29.6 | 17.7 | 31.4 | 19.5 |
| ORR, n (%)* | 17 (73.9) | 11 (61.1) | 21 (84.0) | 20 (58.8) | 62 (88.6) | 56 (77.8) | 72 (93.5) | 69 (70.4) |
| . | High risk . | Standard risk . | ||||||
|---|---|---|---|---|---|---|---|---|
| 1 Prior line . | ≥2 Prior lines . | 1 Prior line . | ≥2 Prior lines . | |||||
| KRd (n = 23) . | Rd (n = 18) . | KRd (n = 25) . | Rd (n = 34) . | KRd (n = 70) . | Rd (n = 72) . | KRd (n = 77) . | Rd (n = 98) . | |
| PFS, median mo | 24.1 | 14.0 | 22.2 | 12.0 | 29.6 | 17.7 | 31.4 | 19.5 |
| ORR, n (%)* | 17 (73.9) | 11 (61.1) | 21 (84.0) | 20 (58.8) | 62 (88.6) | 56 (77.8) | 72 (93.5) | 69 (70.4) |
Determined by Independent Review Committee according to International Myeloma Working Group Uniform Response Criteria. Patients evaluated for ORR had a best overall response of partial response or better.